MTS109 for Hard-to-Treat Autoimmune Diseases
Part of Bones, joints & muscles, Brain & nervous system, Eyes & vision, Heart & circulation, Immune system & allergy, Mouth & dental, Skin clinical trials.
This early-stage trial tests a new treatment called MTS109 for autoimmune diseases (like lupus, muscle inflammation, scleroderma, vasculitis, or Sjögren's syndrome) that haven't responded well to standard medications. The goal is to see if MTS109 can help control disease that keeps flaring or getting worse despite current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Ages 18–65 with one of five specific autoimmune diseases: SLE (lupus), IIM (inflammatory muscle disease), SSc (scleroderma), AAV (vasculitis), or Sjögren's syndrome
- Your disease must be 'refractory' (not responding to standard therapy for 6+ months) or relapsing/progressive despite treatment
- Disease must be active and moderate-to-severe at screening based on specific blood tests and clinical measures
- Normal or near-normal liver, kidney, blood cell counts, and heart function (no severe heart failure or recent heart attack)
- No active infections (HIV, hepatitis B/C, TB, active viral infection), no cancer in past 5 years, no other autoimmune diseases
- Must stop certain immunosuppressive drugs weeks before the trial starts and avoid specific therapies during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a new treatment called YTS109 for children aged 5 to 18 with certain autoimmune diseases that have not gotten better with standard therapies. The treatment targets and possibly removes a type of immune cell that may be causing the disease.
This study tests a new cell therapy (YTS109) for people with autoimmune diseases like lupus or Sjogren's syndrome that have not improved or keep coming back after standard treatments. It aims to see if the treatment can help control the disease.
This early-phase trial tests a new drug called TI-0032-III for people with several autoimmune diseases that haven't gotten better with standard treatments. It aims to see if the drug can safely reduce disease activity and offer a new option for people who have few choices left.
This trial tests a new cell therapy called UTAA91 for people with autoimmune diseases that have not responded to standard treatments. It aims to see if this treatment can help control the disease.
This trial tests an investigational drug called OL-108 for people with certain autoimmune diseases (lupus, myositis, scleroderma, or vasculitis) that have come back or not responded to standard treatments. The goal is to see if it's safe and if it can help control the disease.
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.